Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the execution of an agreement with contract research organization (CRO) CellCarta to manage translational assays for the Company's upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia (AML). This is important progress as the Company prepares to enroll patients in the trial, as CellCarta will be

New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting preclinical results of lead compound CER-1236 in ovarian cancer during the Spring Scientific from the Society for Immunotherapy of Cancer (SITC) in San Diego, March 12-14. The poster, titled, "TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells with

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides investors with a corporate update highlighting its improved cash balance following its recent capital raise, steady progress in the initiation of its Phase 1 clinical trial of CER-1236, and a pathway toward maintaining Nasdaq listing. CEO Chris Ehrlich commented, "We have had a very strong e

SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced the pricing of its "reasonable best efforts" public offering with participation from a member of the Company's board and a single institutional investor for the purchase and sale of 2,551,020 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,551,020 shares of common stock at a combined purchase price of $1.96 (the "Offering"). The warrants w

SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market ("Nasdaq") as of the opening o

SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) --   CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO.  Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution. 

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML). Interim CEO Chris Ehrlich commented, "Following our productive discussions with FDA, we look forward to initiating our first in-human trial of CER-1236 in

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.  The data were presented in a poster at the Society for Immunology of Cancer (SITC) 2024 conference held in Houston November 6-10, 2024. Interim CEO Chri

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich. To our Valued Stockholders: Following the events of the last several months, I believe it appropriate to discuss our recent progress and illuminate the path forward for CERo. As you know, we received notice of a clinical hold for CERO-1236 earlier this year.

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich.   Andrew Albert "Al" Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. "I believe we have the team in place to successfully drive CERo forward into the clinic and to create the Company we have promised our shareholders.  These new management team

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

SCHEDULE 13D/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

EFFECT - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

S-1/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) --   CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO.  Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution.